Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab ± Tremelimumab consolidation in limited-stage small cell lung cancer
NCT03703297Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2018
- Primary completion
- Jan 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial in small cell lung cancer (SCLC) comparing Durvalumab + Placebo, Durvalumab + Tremelimumab and Placebo + Placebo (3 arms). Primary endpoints: Progression-Free Survival and Overall Survival. Started Sep 2018; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03703297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03703297.